@entity16593 ( @entity16593 ) is an infrequent disease with a poor prognosis. We present the clinical and biological features of 41 @entity1 . Median age was 67 years [42-89] and male-female sex ratio was 2.4. The immunophenotyping revealed B-cell phenotype, with a high level expression of surface IgM and/or IgD in all cases, FMC7+ in 76 % of cases and CD5+ in 67%. Marked spontaneous in-vitro apoptosis was observed in most cases tested (n = 12). The median overall survival time was 5 years and the event-free survival time was 37 months. As detected by univariate and multivariate analysis, the only variables associated with a poor prognosis were advanced age and @entity417 . No significant difference was observed between de novo @entity5731 (n = 27) and prolymphocytoid transformation of @entity1072 (n = 14). Two groups of @entity1 were individualized according to their clinical course: @entity1 who died within one year of diagnosis (n = 14) and @entity1 who had a prolonged survival (n = 23) without any treatment in some cases. The comparison between the 2 groups showed that they differed in age (p = 0.01) and @entity417 (p = 0.02). We also observed that the @entity1 with @entity876 mutations had a worse clinical outcome. Taken together these data confirm that @entity16593 should be regarded as a distinct form of @entity1071 and suggest the existence of two patterns of clinical evolution.

A multicentric study of 41 cases of XXXX : two evolutive forms.

@entity16593 :: ('MESH:D054403', 'Disease') :: ['B-prolymphocytic leukemia', 'B-PLL'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity5731 :: ('CHEBI:61490', 'Chemical') :: ['PLL'] @entity1071 :: ('MESH:D008232', 'Disease') :: ['chronic lymphoproliferative disorder'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['chronic lymphocytic leukemia'] @entity876 :: ('7157', 'Gene') :: ['p53']
@entity16593 :: (MESH:D054403,Disease) :: ['B-prolymphocytic leukemia']
